- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 14/525 - Tumour necrosis factor [TNF]
Patent holdings for IPC class C07K 14/525
Total number of patents in this class: 747
10-year publication summary
|
62
|
81
|
54
|
67
|
51
|
52
|
61
|
40
|
43
|
25
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Modernatx, Inc. | 1292 |
23 |
| Apogenix AG | 67 |
19 |
| Universiteit Gent | 1406 |
19 |
| Vib VZW | 908 |
19 |
| Philogen S.p.A. | 128 |
15 |
| Universitat Stuttgart | 271 |
14 |
| Centre National de La Recherche Scientifique | 11026 |
13 |
| Centre hospitalier Regional universitaire de Montpellier | 32 |
13 |
| Shattuck Labs, Inc. | 120 |
13 |
| The General Hospital Corporation | 4871 |
12 |
| UCB Biopharma SRL | 600 |
11 |
| Cedars-Sinai Medical Center | 1207 |
10 |
| Sanofi Aatd Inc. | 17 |
10 |
| Universite de Montpellier | 1041 |
9 |
| Hoffmann-La Roche Inc. | 3796 |
8 |
| Apeptico Forschung und Entwicklung GmbH | 35 |
8 |
| Memed Diagnostics Ltd. | 80 |
8 |
| Thomas Jefferson University | 555 |
8 |
| Xencor, Inc. | 414 |
8 |
| Orionis Biosciences BV | 81 |
8 |
| Other owners | 499 |